839 Investors Fought Over Every Share of This Korean Biotech's IPO
A South Korean biotech with no drugs on the market just drew 839-to-1 institutional demand for its IPO, pricing at the top of its range. Behind the frenzy: a near-billion-dollar licensing deal with a US partner backed by one of biotech's biggest venture firms.
The Hottest Ticket in Seoul Wasn't a Concert
Imagine 839 people showing up to buy the same house. That's essentially what happened when South Korean biotech IM Biologics opened its books to institutional investors ahead of its KOSDAQ listing. The company's IPO attracted an 839-to-1 institutional competition rate, with 2,333 institutions from Korea and abroad piling in for a chance to own shares.
The kicker? IM Biologics doesn't have a single drug on the market. Its lead assets are still in early clinical trials. And yet investors priced the offering at 26,000 KRW per share (roughly $18.50), the absolute top of its 19,000–26,000 KRW indicative range. The company raised approximately 52 billion KRW (~$37 million) and is set to debut on KOSDAQ on March 20 with a projected market cap of about 384 billion KRW.
So what's driving this frenzy for a company most people outside Korea have never heard of?
A Billion-Dollar Handshake With a US Partner
The story starts in June 2024, when a brand-new US biotech called Navigator Medicines signed a licensing deal for IM Biologics' two lead programs: IMB-101 and IMB-102. The structure of that deal tells you everything about how seriously the Americans took this science.
Navigator paid $20 million upfront and committed to milestone payments totaling up to $924.75 million, making the deal worth nearly $1 billion in total. IM Biologics also gets double-digit royalties on future sales. In return, Navigator got global commercialization rights outside of Asia (but including Japan).
Who's bankrolling Navigator? RA Capital Management, one of the biggest biotech venture firms in the US, co-led a $100 million Series A round alongside Forbion specifically to fund development of these assets. RA Capital partner Andrew Levin joined Navigator's board, which in biotech circles is the equivalent of a Michelin-starred chef agreeing to run your kitchen.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
IM Biologics' crown jewel is IMB-101, now called NAV-240 under Navigator's roof. It's a bispecific antibody, which means it's engineered to grab onto two different disease targets at once. Think of it like a wrench that fits two different bolt sizes simultaneously.
The two targets are OX40L and TNFα, both well-known drivers of inflammation. TNFα is the same target that blockbuster drugs like Humira go after; OX40L plays a key role in revving up immune cells that attack your own body. By hitting both at the same time, IMB-101 could potentially work in patients where single-target drugs fall short, particularly people with complex autoimmune conditions like rheumatoid arthritis.
Navigator reported positive Phase 1a data in September 2025 and completed its Phase 1b trial (with actual patients, not just healthy volunteers) by November 2025. The company is now gearing up for Phase 2a trials in the US, targeting people with hidradenitis suppurativa, a painful skin condition with limited treatment options.
The second asset, IMB-102, is a more traditional monoclonal antibody focused solely on OX40L. It's earlier in development but adds depth to the portfolio.
The Platform Behind the Pipeline
IM Biologics isn't just a one-trick pony. The company built a proprietary discovery engine called ePENDY that's designed to rapidly generate antibodies for immune modulation. Think of it as a factory that can custom-build different types of wrenches for different biological problems.
The platform has already been presented at major scientific conferences (AACR, ACR) and earned a Korean patent in January 2025. It's spawned additional programs in oncology, including IMB-201, IMB-401, and IMB-402, all in earlier stages. A partnership with Dong-A ST suggests the technology has broader applications beyond what IM Biologics is pursuing on its own.
Founded in 2020 by Gyongsik Ha, Ph.D., the company spun out of an antibody research team at HK inno.N. In just four years, Ha's team went from seed funding (4 billion KRW) through Series A and B rounds totaling about 33 billion KRW, secured FDA clearance to start US clinical trials, and landed a near-billion-dollar licensing deal. That's a sprint by any standard.
Korea's Biotech IPO Market Is Running Hot
IM Biologics' blockbuster subscription numbers aren't happening in a vacuum. South Korea's biotech IPO market has been on fire. Kanaph Therapeutics recently posted an even higher institutional competition rate of 962-to-1 for its own KOSDAQ listing. Immuneoncia Therapeutics drew 897-to-1 demand last year and saw its shares close 108% above the offering price on day one.
Every single biotech book-building in 2026 has priced at the top of its range. The KOSDAQ index crossed 1,000 in January 2026 for the first time in four years, creating a tailwind for new listings. Korean institutional investors, who once looked primarily at domestic opportunities, are increasingly betting on companies with validated US partnerships and global ambitions.
The 76% lock-up rate among institutional investors in IM Biologics' offering is particularly telling. That means three out of four institutional buyers agreed to hold their shares for a set period rather than flip them on listing day. When sophisticated investors voluntarily lock up their capital in a preclinical-stage biotech, they're signaling genuine long-term conviction, not just momentum trading.
Why This Matters Beyond Seoul
The IM Biologics IPO is a case study in how Asia-Pacific biotech is evolving. A Korean company invents the science, licenses it to a US startup backed by elite American venture capital, and then uses the validation from that deal to raise money from Korean public markets. Everyone gets what they want: Navigator gets promising drug candidates; IM Biologics gets funded to build more; and Korean investors get exposure to globally relevant science.
Only about 23% of IM Biologics' shares will be freely tradable after listing, which could create a supply squeeze if demand stays anywhere near current levels. With IPO proceeds earmarked for expanding its preclinical pipeline and the Navigator partnership generating milestones as NAV-240 advances through Phase 2, the company has fuel for the next several years.
Whether the stock delivers on listing day is anyone's guess. But when 839 institutions fight over your shares before you've sold a single pill, something is clearly working.
Clinical & Regulatory
4 min read
Iran Just Hacked One of America's Biggest Medical Device Makers
An Iran-linked hacking group just hit Stryker, one of the world's largest medical device companies, wiping 200,000 systems and claiming to steal 50 terabytes of data. The attack didn't compromise surgical robots or defibrillators, but it exposes a terrifying vulnerability in the healthcare supply chain.
